Which Weight Management Treatment Suits You Better?
Private Prescription Advantage: Wegovy or Mounjaro Better Access
The NHS route for accessing weight management medications involves GP referral to specialist services, often resulting in 6+ month waiting lists and strict eligibility criteria. Private prescription eliminates these barriers, allowing direct access to both Wegovy and Mounjaro through qualified prescribers. EverydayMeds operates as a GPhC-registered pharmacy (#9012878), supplying the same genuine medications available through NHS channels.
Whether Wegovy or Mounjaro better fits your circumstances depends on individual factors like dosing preferences, storage requirements, and clinical history. Private prescription allows personalised prescriber consultation without lengthy NHS processes. Both treatments require ongoing prescription-only medicine monitoring, which our clinical team provides alongside your treatment journey.
Wegovy vs Mounjaro Pricing: Private Prescription Costs
Wegovy pricing starts at £79.99 for 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for maintenance 2.4mg doses. Our Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing your first two months of treatment. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 for continued savings.
Mounjaro follows a different pricing structure with its tirzepatide formulation. Both treatments require dose escalation over 16-20 weeks to reach maintenance levels. When considering whether Wegovy or Mounjaro better suits your budget, factor in the complete dose escalation journey rather than just starter costs. Our bundle options provide treatment continuity without repeated ordering.
Clinical Evidence: Wegovy and Mounjaro Efficacy Data
The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 showed 9.6% average weight loss in patients with type 2 diabetes, while STEP 3 achieved 16% with intensive behavioural therapy.
Mounjaro's SURMOUNT trials used different methodologies and patient populations, making direct percentage comparisons inappropriate. Both medications demonstrated significant weight management support in their respective clinical programmes. Whether Wegovy or Mounjaro better suits individual patients depends on their medical history, which qualified prescribers assess during clinical review.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. This prescription-only medicine works by reducing appetite and promoting satiety after smaller meals, potentially reducing food cravings through brain appetite centres. The once-weekly injection using Novo Nordisk's FlexTouch pen provides consistent medication levels throughout the week. Wegovy must be used alongside a reduced-calorie diet and increased physical activity for optimal results. The treatment works gradually, with full effects typically developing over several months of consistent use.
EverydayMeds Ordering Process: Simple Private Prescription
Our streamlined process begins with a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Qualified prescribers review your assessment within 3 working days (24 hours with express service), determining whether Wegovy or Mounjaro better suits your clinical profile. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain logistics. All orders include comprehensive patient information leaflets and injection guidance. Follow-up prescriber support ensures ongoing monitoring throughout your treatment journey.
Storage and Practical Considerations
Wegovy offers storage advantages over Mounjaro, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. Both require initial refrigerated storage at 2-8°C before first use. The FlexTouch pen design provides precise dosing with clear dose counters and safety features. Dose escalation follows a mandatory schedule over 16 weeks, starting at 0.25mg weekly and increasing gradually to 2.4mg maintenance dose. Neither medication allows dose skipping, making consistent weekly administration essential for tolerance and efficacy.
Mechanism Differences: Single vs Dual Hormone Action
The fundamental difference when considering Wegovy or Mounjaro better lies in their hormone targets. Wegovy activates GLP-1 receptors exclusively, while Mounjaro targets both GLP-1 and GIP receptors through its tirzepatide formulation. This dual mechanism may offer different appetite and glucose regulation patterns, though individual responses vary significantly.
Both medications require prescription-only medicine classification due to their potent hormonal effects and potential side effects. Private prescription allows detailed discussion of these mechanism differences with qualified prescribers, helping determine optimal treatment selection. EverydayMeds provides both options, ensuring access regardless of which proves more suitable for individual patients.
Start Your Weight Management Journey Today
Both Wegovy and Mounjaro are available through EverydayMeds' private prescription service, eliminating NHS waiting lists and providing immediate access to qualified prescriber assessment. New customers use code FIRST40 at checkout for starter dose pricing from £79.99, while returning customers apply DOSE25 for continued savings. Our GPhC-registered pharmacy (#9012878) ensures genuine medication supply with next-day delivery once approved. Whether Wegovy or Mounjaro better suits your needs, our clinical team provides ongoing support throughout your treatment journey. Begin your 3-minute assessment today at https://everydaymeds.co.uk/collections/wegovy and take the first step toward effective weight management.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
